Otezla

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

apremilast

Available from:

Amgen Europe BV

ATC code:

L04AA32

INN (International Name):

apremilast

Therapeutic group:

Imunosupresivi

Therapeutic area:

Arthritis, Psoriatic; Psoriasis

Therapeutic indications:

Psoriatični arthritisOtezla, samostojno ali v kombinaciji z Boleznijo Spreminjanje Antirheumatic Drugs (DMARDs), je primerna za zdravljenje aktivnega psoriatičnega artritisa (PsA) pri odraslih bolnikih, ki so imeli ustreznega odgovora, ali ki so bili nestrpni, da pred terapijo DMARD. PsoriasisOtezla je primerna za zdravljenje zmerno do hudo kronično psoriazo v plakih pri odraslih bolnikih, ki odzvali na ali ki so kontraindikacija za, ali so nestrpni do drugih sistemsko terapijo, vključno z ciklosporin, metotreksat ali psoralen in uv-svetlobe (PUVA).

Product summary:

Revision: 21

Authorization status:

Pooblaščeni

Authorization date:

2015-01-15

Patient Information leaflet

                                27
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Amgen Europe B.V.
Minervum 7061,
4817 ZK Breda,
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/981/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
_ _
16.
PODATKI V BRAILLOVI PISAVI
Otezla 10 mg
Otezla 20 mg
Otezla 30 mg
28
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
29
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT (PODATKI, NATISNJENI NEPOSREDNO NA ZGIBANKO, PRETISNI
OMOT BREZ NAPISA PA JE
ZAPEČATEN ZNOTRAJ)
1.
IME ZDRAVILA
Otezla 10 mg tablete
Otezla 20 mg tablete
Otezla 30 mg tablete
apremilast
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Amgen
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
30
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Otezla 30 mg filmsko obložene tablete
apremilast
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
_ _
Ena filmsko obložena tableta vsebuje 30 mg apremilasta.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo. Za nadaljnje informacije glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
56 filmsko obloženih tablet
168 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
Za peroralno uporabo.
Vsebuje QR kodo
www.otezla-eu-pil.com
_ _
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
31
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Otezla 10 mg filmsko obložene tablete
Otezla 20 mg filmsko obložene tablete
Otezla 30 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Otezla 10 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 10 mg apremilasta.
_Pomožna snov z znanim učinkom: _
Ena filmsko obložena tableta vsebuje 57 mg laktoze (v obliki laktoze
monohidrata).
Otezla 20 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 20 mg apremilasta.
_Pomožna snov z znanim učinkom: _
Ena filmsko obložena tableta vsebuje 114 mg laktoze (v obliki laktoze
monohidrata).
Otezla 30 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 30 mg apremilasta.
_Pomožna snov z znanim učinkom: _
Ena filmsko obložena tableta vsebuje 171 mg laktoze (v obliki laktoze
monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Otezla 10 mg filmsko obložene tablete
Rožnata 10 mg filmsko obložena tableta v obliki romba, dolžine 8
mm, z vtisnjenim napisom “APR”
na eni strani in “10” na drugi strani.
Otezla 20 mg filmsko obložene tablete
Rjava 20 mg filmsko obložena tableta v obliki romba, dolžine 10 mm,
z vtisnjenim napisom “APR” na
eni strani in “20” na drugi strani.
Otezla 30 mg filmsko obložene tablete
Bež 30 mg filmsko obložena tableta v obliki romba, dolžine 12 mm, z
vtisnjenim napisom “APR” na
eni strani in “30” na drugi strani.
3
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Psoriatični artritis
Zdravilo Otezla, samo ali v kombinaciji z imunomodulirajočimi
protirevmatičnimi zdravili (DMARDs
-
_Disease Modifying Antirheumatic Drugs_
), je indicirano za zdravljenje aktivnega psoriatičnega
artritisa (PsA) pri odraslih bolnikih, ki so se nezadostno odzvali na
predhodno zdravljenje z DMARD
ali ga niso prenašali (glejte poglavje 5.1).
Psoriaza
Zdravilo Otezla je indicirano za zdravljenje zmerne do hude kronične
psoriaze (PSOR) 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-07-2022
Public Assessment Report Public Assessment Report Bulgarian 05-03-2024
Patient Information leaflet Patient Information leaflet Spanish 21-07-2022
Public Assessment Report Public Assessment Report Spanish 05-03-2024
Patient Information leaflet Patient Information leaflet Czech 21-07-2022
Public Assessment Report Public Assessment Report Czech 05-03-2024
Patient Information leaflet Patient Information leaflet Danish 21-07-2022
Public Assessment Report Public Assessment Report Danish 05-03-2024
Patient Information leaflet Patient Information leaflet German 21-07-2022
Public Assessment Report Public Assessment Report German 05-03-2024
Patient Information leaflet Patient Information leaflet Estonian 21-07-2022
Public Assessment Report Public Assessment Report Estonian 05-03-2024
Patient Information leaflet Patient Information leaflet Greek 21-07-2022
Public Assessment Report Public Assessment Report Greek 05-03-2024
Patient Information leaflet Patient Information leaflet English 21-07-2022
Public Assessment Report Public Assessment Report English 05-03-2024
Patient Information leaflet Patient Information leaflet French 21-07-2022
Public Assessment Report Public Assessment Report French 05-03-2024
Patient Information leaflet Patient Information leaflet Italian 21-07-2022
Public Assessment Report Public Assessment Report Italian 05-03-2024
Patient Information leaflet Patient Information leaflet Latvian 21-07-2022
Public Assessment Report Public Assessment Report Latvian 05-03-2024
Patient Information leaflet Patient Information leaflet Lithuanian 21-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-07-2022
Public Assessment Report Public Assessment Report Lithuanian 05-03-2024
Patient Information leaflet Patient Information leaflet Hungarian 21-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 21-07-2022
Public Assessment Report Public Assessment Report Hungarian 05-03-2024
Patient Information leaflet Patient Information leaflet Maltese 21-07-2022
Public Assessment Report Public Assessment Report Maltese 05-03-2024
Patient Information leaflet Patient Information leaflet Dutch 21-07-2022
Public Assessment Report Public Assessment Report Dutch 05-03-2024
Patient Information leaflet Patient Information leaflet Polish 21-07-2022
Public Assessment Report Public Assessment Report Polish 05-03-2024
Patient Information leaflet Patient Information leaflet Portuguese 21-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 21-07-2022
Public Assessment Report Public Assessment Report Portuguese 05-03-2024
Patient Information leaflet Patient Information leaflet Romanian 21-07-2022
Public Assessment Report Public Assessment Report Romanian 05-03-2024
Patient Information leaflet Patient Information leaflet Slovak 21-07-2022
Public Assessment Report Public Assessment Report Slovak 05-03-2024
Patient Information leaflet Patient Information leaflet Finnish 21-07-2022
Public Assessment Report Public Assessment Report Finnish 05-03-2024
Patient Information leaflet Patient Information leaflet Swedish 21-07-2022
Public Assessment Report Public Assessment Report Swedish 05-03-2024
Patient Information leaflet Patient Information leaflet Norwegian 21-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 21-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 21-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 21-07-2022
Patient Information leaflet Patient Information leaflet Croatian 21-07-2022
Public Assessment Report Public Assessment Report Croatian 05-03-2024

Search alerts related to this product

View documents history